Merck & Co.'s Q1 2022 earnings call highlighted several positive factors that are likely to have a favorable short-term impact on the stock price. Here are the key points:

- **Strong Financial Performance**: Merck reported robust top and bottom-line growth, with worldwide sales increasing by 50% to $15.9 billion, driven by significant contributions from KEYTRUDA, GARDASIL, and LAGEVRIO[4|.
- **Updated Guidance**: The company raised and narrowed its full-year 2022 guidance, expecting revenue between $56.9 billion and $58.1 billion, which reflects strong growth prospects[4|.
- **Clinical Advancements**: Merck made several clinical advancements, including new approvals and encouraging data from various trials, particularly in oncology and cardiovascular diseases. This reinforces the company's science-led strategy and its potential for long-term growth[4|.
- **Market Leadership**: KEYTRUDA and GARDASIL continued to show strong growth, with KEYTRUDA expanding its market share in new indications and GARDASIL benefiting from increased supply and global demand[4|.
- **Business Development**: Despite challenges in the biotech market, Merck remains focused on strategic business development to augment its pipeline, indicating a proactive approach to growth[4].

Given these strong results, updated guidance, and continued clinical and commercial success, the stock is likely to experience a positive impact in the short term.

[2]